NCT06412198View on ClinicalTrials.gov

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2028

Conditions
Metastatic Colorectal CancerKRAS G12C Mutations
Interventions
DRUG

Cetuximab

Given by IV

DRUG

Cemiplimab

Given by IV

DRUG

Adagrasib

Given by PO

Trial Locations (2)

77030

RECRUITING

MD Anderson Cancer Center, Houston

02114

NOT_YET_RECRUITING

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER